These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36635351)

  • 1. PDJ amplicon in triple negative breast cancer.
    Roesler AS; Malasi S; Koslosky L; Hartmayer P; Naab TJ; Carter JM; Zahrieh D; Hillman D; Leon-Ferre RA; Couch FJ; Goetz MP; Anderson KS; Pockaj BA; Barrett MT
    Sci Rep; 2023 Jan; 13(1):618. PubMed ID: 36635351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
    Chen M; Andreozzi M; Pockaj B; Barrett MT; Ocal IT; McCullough AE; Linnaus ME; Chang JM; Yearley JH; Annamalai L; Anderson KS
    Mod Pathol; 2017 Nov; 30(11):1516-1526. PubMed ID: 28752839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
    Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer.
    Zhao H; Ma W; Fragoso RC; Iv GRH; Ashok A; Li T
    J Natl Cancer Cent; 2021 Sep; 1(3):115-121. PubMed ID: 39036375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
    Hoda RS; Brogi E; Dos Anjos CH; Grabenstetter A; Ventura K; Patil S; Selenica P; Weigelt B; Reis-Filho JS; Traina T; Robson M; Norton L; Wen HY
    Mod Pathol; 2020 Nov; 33(11):2221-2232. PubMed ID: 32612248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
    Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
    Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
    Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
    Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
    [No Abstract]   [Full Text] [Related]  

  • 18. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
    Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
    Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
    J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.